Breast cancer is one of the most survivable cancers. The overall 5-year relative survival rate for women diagnosed with breast cancer in the United States is roughly 91%, and when the cancer is caught before it spreads beyond the breast, that number climbs even higher. But “how survivable” depends heavily on when it’s found, what type it is, and who’s being diagnosed.
Survival by Stage at Diagnosis
Stage at diagnosis is the single biggest factor in breast cancer survival. The national cancer surveillance system (SEER) groups cases into three broad categories: localized (cancer confined to the breast), regional (spread to nearby lymph nodes), and distant (spread to other organs like the bones, lungs, or liver).
For localized breast cancer, the 5-year relative survival rate is above 99%. That means women diagnosed at this stage are almost as likely to be alive five years later as women who were never diagnosed at all. Regional breast cancer, where the cancer has reached nearby tissue or lymph nodes, drops to roughly 86-88% for most subtypes. Distant, or metastatic, breast cancer has the lowest survival rate, though even here outcomes have improved dramatically in recent years.
About 65% of breast cancers are caught at the localized stage, which is a major reason the overall numbers look so favorable. Regular mammography screening reduces breast cancer mortality by approximately 25% in the general population, largely because it catches tumors before they spread.
Metastatic Breast Cancer Is Improving
A diagnosis of stage IV breast cancer used to carry a median survival of about two years. That’s changed. A 2025 study published in ESMO Open compared three groups of patients diagnosed across different eras: those diagnosed between 2004 and 2009 had a median survival of 25 months, while those diagnosed between 2016 and 2021 reached a median survival of 49 months, nearly doubling the earlier figure. Newer targeted therapies and immunotherapies are behind much of that improvement.
The 5-year survival rate for distant breast cancer still sits around 30% overall, so metastatic disease remains serious. But the trajectory is clearly moving in the right direction, and some patients live well beyond the median.
How Cancer Subtype Affects the Numbers
Not all breast cancers behave the same way. The most common subtypes, hormone receptor-positive cancers, tend to grow more slowly and respond well to long-term hormone-blocking treatments. These carry the highest survival rates.
Triple-negative breast cancer (TNBC) is more aggressive. It accounts for about 10-15% of breast cancers and tends to grow quickly, is more likely to have already spread at the time of diagnosis, and is more likely to come back after treatment. The numbers reflect this: the 5-year survival rate for TNBC across all stages combined is 78%, compared to 91% for breast cancer overall. When caught early (localized), TNBC survival is still 92%. But for distant TNBC, that drops to just 15%.
Age, Race, and Sex Matter
Women diagnosed at older ages face worse outcomes. SEER data notes that women diagnosed at an advanced age are more likely to die of the disease than younger women, partly because older patients may have other health conditions that limit treatment options or because their cancers are diagnosed at a later stage.
Race creates a significant and persistent gap. Black women have a 6% to 8% lower 5-year survival rate than White women across every breast cancer subtype. The disparity is starkest at later stages: 78% of Black women survive at least five years after a regional-stage diagnosis compared to 88% of White women. For distant-stage disease, the gap is 21% versus 32%. These differences stem from a mix of factors including later diagnosis, differences in tumor biology, and unequal access to high-quality care.
Men can also develop breast cancer, though it’s rare. The 5-year overall survival rate for men with breast cancer is 77.6%, compared to 86.4% for women. Part of this gap likely reflects later diagnosis, since men are less likely to expect or recognize breast cancer symptoms.
Recurrence Risk Over Time
Surviving the first five years doesn’t mean the risk disappears entirely. In a long-term follow-up study spanning 24 years, the annual risk of recurrence was highest in the first five years at about 10.4% per year, peaking between years one and two at 15.2%. After that, the risk drops significantly but never reaches zero. Between years 10 and 15, the annual recurrence risk was 2.2%. Between years 15 and 20, it fell to 1.5%. By years 20 to 25, it was just 0.7%.
This pattern is especially relevant for hormone receptor-positive cancers, which can recur late. It’s one reason some patients are recommended to continue hormone-blocking therapy for 10 years rather than five. For triple-negative breast cancer, recurrences tend to cluster in the first three to five years. If you reach the five-year mark without recurrence with TNBC, your long-term outlook improves considerably.
Screening Makes a Measurable Difference
For breast cancer survivors specifically, continued screening after treatment provides an additional layer of protection. A population-based study found that breast cancer survivors who participated in mammography screening had a 36-38% lower risk of dying from breast cancer compared to similar survivors who were not invited to screen. Even when comparing invited versus non-invited groups (regardless of whether they actually attended), there was still a 10-12% mortality reduction, suggesting that the screening infrastructure itself catches second cancers earlier.
For the general population, the roughly 25% mortality reduction from regular mammography largely comes down to detecting cancer at the localized stage, where survival is near 100%, rather than at a regional or distant stage where outcomes are significantly worse.